: Affimed started at buy with $10 stock price target at Truist

: Affimed started at buy with $10 stock price target at Truist

: Affimed started at buy with $10 stock price target at Truist

Affimed N.V.

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.